Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Massachusetts"

42 News Found

AstraZeneca’s new R&D Centre and Alexion HQ in Cambridge, Massachusetts
News | May 01, 2022

AstraZeneca’s new R&D Centre and Alexion HQ in Cambridge, Massachusetts

Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub


AbbVie begins construction of $70 million biologics manufacturing site in US
News | October 01, 2025

AbbVie begins construction of $70 million biologics manufacturing site in US

The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology


Takeda appoints Rhonda Pacheco President of US Business Unit
People | September 13, 2025

Takeda appoints Rhonda Pacheco President of US Business Unit

Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO


Merck appoints David Weinreich as new Global Head of R&D and CMO for Healthcare Business
People | September 03, 2025

Merck appoints David Weinreich as new Global Head of R&D and CMO for Healthcare Business

He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career


Merck and mantro launch EdiMembre to transform alternative protein industry
News | August 18, 2025

Merck and mantro launch EdiMembre to transform alternative protein industry

Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry


AstraZeneca plans to invest $50 billion in US by 2030
News | July 22, 2025

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US


Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Clinical Trials | July 21, 2025

Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population


Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US
News | April 07, 2025

Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US

Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013


Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas
Drug Approval | January 19, 2025

Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas

This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo


Sartorius Stedim Biotech opens center for bioprocess innovation in USA
Biotech | November 22, 2024

Sartorius Stedim Biotech opens center for bioprocess innovation in USA

New research labs and process development services to enable next generation therapeutics